Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Agent Found to Suppress Cognitive Impairment of Alzheimer’s Disease

By BiotechDaily International staff writers
Posted on 25 Nov 2013
A unique new compound has been shown to prevent cognitive impairment and oxidative stress in animal lab models and may ultimately be useful in treating Alzheimer’s disease (AD).

This new findings on the compound, IRL-1620, were presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition, the world’s largest pharmaceutical sciences meeting, held in San Antonio (TX, USA), November 10-14, 2013.

Anil Gulati, MD, PhD, FCP, and Seema Briyal, PhD, along with their colleagues from Midwestern University (Downers Grove, IL, USA), administered Amyloid beta (Aβ), a key component of specific deposits located in AD patients’ brains, to normal and diabetic rats on days 1, 7, and 14. The lab rat’s spatial learning and memory were assessed in a Morris water maze. The pool was separated into four equal quadrants, and an escape platform was hidden below the surface at a fixed location in one of the quadrants.

The rats had to locate the platform within 60 seconds. The average time it took on day 4 for Aβ-treated rats to locate the platform was 55.05 seconds, though most of this group was not able to find it in the allotted time. Aβ rats treated with IRL-1620 were able to find the platform in 26.53 seconds, nearly 50% the time. After five days, Aβ rats treated with IRL-1620 showed a 60% improvement in learning and memory.

“Our research is based on the idea of using the endothelin [ET] system in the treatment of AD,” said Dr. Gulati. “The ET system is traditionally known to play a role in the regulation of blood flow. This is important in the potential treatment of AD since disturbances in blood flow could damage the brain’s ability to clear damaging particles, leading to a buildup of toxic substances and cognitive impairment.”

The next stage of the research is to additionally study the endothelin receptor type B’s mechanisms of neuroprotection and to look into possible resulting tissue changes following AD.

The US Food and Drug Administration (FDA) has approved five medications to treat the symptoms of AD. Current agents help disguise the symptoms but do not treat the underlying disease. A breakthrough AD treatment would target the underlying disease and stop or delay the cell damage that ultimately leads to the aggravation of symptoms.

Related Links:

Midwestern University



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.